25 February 2018
News and Views
Links and Services
The latest publication of the Alimentary Pharmacology & Therapeutics examines the patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens.
Interferon and ribavirin negatively impact health-related quality of life (HRQL) during treatment
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors